Cited by 89Pharmacogenetics and Drug MetabolismDrug Transport and Resistance MechanismsPharmaceutical studies and practices

The DOI matches its Crossref record.

Organ Clearance Concepts: New Perspectives on Old Principles

Sirianni, Gina L., Pang, K. Sandy·1997·Journal of Pharmacokinetics and Biopharmaceutics

Abstract

The removal capacity of an eliminating organ by metabolism and/or excretion is often expressed as its clearance. Metabolic and excretory clearances are considered to be mutually independent, and the sum of these constitute the whole organ clearance. The influence of metabolism on estimates of the excretory clearance and vice versa was examined for the liver and kidney with physiologically based models. Mass transfer first-order rate equations describing transport and removal were derived. Upon inversion of the matrices originating from the coefficients of these equations, the area under the curve (AUC) and clearance (dose/AUC) were obtained with the liver or kidney as the eliminating organ. A more complex solution was found to exist for the kidney since glomerular filtration, secretion; reabsorption, and intrarenal metabolism were present. To ascertain the effect of excretion on estimates of the metabolic clearance as well as the effect of metabolism on estimates of the excretory clearance, intrinsic clearances for excretion or metabolism were set to zero. Clearance values were found to be altered when alternate pathways were present. Whereas excretory clearance estimates were consistently reduced in the presence of metabolism, metabolic clearance estimates were affected differentially by excretion and varied according to the site of metabolism. Excretion reduced metabolic clearance estimates when metabolism occurred intracellularly. If metabolism occurred intraluminally (e.g., on the renal brush border or luminal membrane), the metabolic clearance estimate could become higher since the substrate was made available to the enzymes following its excretion. As expected, these changes depended on the relative magnitudes of the intrinsic clearances for metabolism and excretion. The above theory was applied to the elimination of enalapril which is both metabolized and excreted by the perfused rat liver and kidney preparations. Data obtained in these studies were consistent with a set of published physiologic parameters denoting transfer and intrinsic clearances. Perturbations on clearance estimates were studied by setting the metabolic/excretory intrinsic clearance to zero, then to some finite value. In liver, the avid hepatocellular metabolism of enalapril reduced biliary clearance by 73%. For the kidney, the fractional excretion (FE or unbound excretory clearance/glomerular filtration rate) was decreased modestly (from 0.64 to 0.44) with intracellular esterolysis, whereas if metabolism had occurred intraluminally, FE would have been significantly decreased (from 1.8 to 0.45). Simulation results show clearly that clearance estimates are affected by the presence of alternate removal pathways, and question the well-established principle the metabolic and excretory clearance estimates are independent of each other.

Overview

Integrity signals

Registry

Crossref · 10.1023/a:1025792925854

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Research works printed but not linked: 41

  1. N. Gréhant. Mesure de l'activite physiologique des reins par le dosage de l'urée dans la sang et dans l'urine. J. Phyisiol. Pathol. Gen. 6:1–8 (1904).
  2. A. E. Lewis. The concept of hepatic clearance. Am. J. Clin. Pathol. 18:789–795 (1948). · DOI
  3. G. R. Wilkinson. Clearance approaches in pharmacology. Pharmacol. Rev. 39:1–47 (1987). · DOI
  4. K. S. Pang, H. Koster, I. C. M. Halsema, E. Scholtens, G. J. Mulder, and R. N. Stillwell. Normal and retrograde perfusion to probe the zonal distribution of sulfation and glucuronidation activities of harmol in the perfused rat liver preparation. J. Pharmacol. Exp. Ther. 224:647–653 (1983). · DOI
  5. H. Koster, I. Halsema, K. S. Pang, E. Scholtens, and G. J. Mulder. Kinetics of sulfation and glucuronidation of harmol in the perfused rat liver preparation. Disappearance of aberrancies in glucuronidation kinetics by inhibition of sulfation. Biochem. Pharmacol. 31:3023–3038 (1982). · DOI
  6. M. E. Morris and K. S. Pang. Competition between two enzymes for substrate removal in liver: modulating effects of competitive pathways. J. Pharmacokin. Biopharm. 15:473–496 (1987). · DOI
  7. D. E. Smith and A. R. Kugler. Communications. Influence of intrarenal metabolism on the analysis of renal drug transport mechanisms. J. Pharm. Sci. 83:1519–1520 (1994). · DOI
  8. D. E. Smith, A. R. Kugler, and J. B. Schnermann. Reabsorption and metabolism of quinapril and quinaprilat in rat kidney: In vivo micropuncture studies. J. Pharm. Sci. 84:1147–1150 (1995). · DOI
  9. A. R. Kluger, S. C. Olson, and D. E. Smith: Disposition of quinapril and quinaprilat in the isolated perfused rat kidney. J. Pharmacokin. Biopharm. 23:287–305 (1995). · DOI
  10. B. M. Brenner, L. D. Dworkin, and L. Ichikawa. Glomerular ultrafiltration. In B. M. Brenner and F. C. Rector, Jr. (eds.), The Kidney Third Edition, Philadelphia, 1986, pp. 124–144.
  11. K. B. Bishoff and R. L. Dedrick. Thiopental pharmacokinetics. J. Pharm. Sci. 57:346–1351 (1968).
  12. R. Lutz, R. L. Dedrick, and D. S. Zaharko. Physiological pharmacokinetics: An in vivo approach to membrane transport. Pharmacol. Therm. 11:559–592 (1980). · DOI
  13. I. A. M. de Lannoy, H. Hirayama, and K. S. Pang. A physiological model for renal drug metabolism: enalapril esterolysis to enalaprilat in the isolated perfused rat kidney. J. Pharmacokin. Biopharm. 18:561–588 (1990). · DOI
  14. M. Rowland. The influence of route of administration on drug availability. J. Pharm. Sci. 61:70–74 (1972). · DOI
  15. M. Rowland, L. Z. Benet, and G. G. Graham. Clearance concepts in pharmacokinetics. J. Pharmacokin. Biopharm. 1:123–136 (1973). · DOI
  16. P. Hekman and C. A. M. van Ginneken. Kinetic modeling of the renal excretion of iodopyracet in the dog. J. Pharmacokin. Biopharm. 10:77–92 (1982). · DOI
  17. I. A. M. de Lannoy and K. S. Pang. Diffusional barriers on drug and metabolite kinetics. Drug Metab. Dispos. 15:51–58 (1987). · DOI
  18. I. A. M. de Lannoy, F. Barker, III, and K. S. Pang. Formed and preformed metabolite excretion clearances in liver, a metabolite formation organ. Studies with enalapril and enalaprilat in the single pass and recirculating perfused rat liver. J. Pharmacokin. Biopharm. 21:395–422 (1993). · DOI
  19. I. A. M. de Lannoy and K. S. Pang. Combined recirculation of the rat liver and kidney: Studies with enalapril and enalaprilat. J. Pharmacokin. Biopharm. 21:423–456 (1993). · DOI
  20. I. A. M. de Lannoy, R. Nespeca, and K. S. Pang. Renal handling of enalapril and its metabolite, enalaprilat, in the isolated red blood cell-perfused rat kidney. J. Pharmacol. Exp. Ther. 251:1211–1222 (1989). · DOI
  21. A. J. Schwab, F. Barker, III, C. A. Goresky, and K. S. Pang. Transfer of enalaprilat across rat liver cell membranes is barrier-limited. Am. J. Physiol. 258(Gastrointest. Liver Physiol. 21):G461–G475 (1990). · DOI
  22. K. S. Pang, W. F. Lee, W. F. Cherry, V. Yuen, J. Accaputo, S. Fayz, A. J. Schwab, and C. A. Goresky. Effects of perfusate flow rate on measured blood volume, disse space, intracellular water spaces, and drug extraction in the perfused rat liver preparation: characterization by the technique of multiple indicator dilution technique. J. Pharmacokin. Biopharm. 16:595–632 (1988). · DOI
  23. J. Reichen and G. Paumgartner. Excretory function of the liver. In N. B. Javitt (ed.), Liver and Biliary Tract Physiology I. International Review of Physiology, Vol. 21, University Park Press, Baltimore, MD, 1980, pp. 103–150.
  24. A. J. Schwab, I. A. M. de Lannoy, K. Poon, C. A. Goresky, and K. S. Pang. Enalaprilat handling by the rat kidney: barrier-limited cell entry. Am. J. Physiol. 263(Renal Fluid Electrolyte Physiol. 32):F858–F869 (1992).
  25. W. S. Spector. Handbook of Biological Data, W. B. Saunders, Philadelphia, 1956, pp. 75, 341.
  26. G. R. Wilkinson and D. G. Shand. Commentary. A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18:377–390 (1975). · DOI
  27. J. R. Gillette and K. S. Pang. Theoretical aspects of pharmacokinetic drug interactions. Clin. Pharmacol. Ther. 22:623–639 (1977). · DOI
  28. K. S. Pang and M. Chiba. Metabolism: Scaling up from in vitro to organ and whole body. In P. G. Welling and L. P. Balant (eds.), Handbook of Experimental Pharmacology, Springer-Verlag, Stuttgart, 1994, pp. 101–187.
  29. F. H. Noormohamed, W. R. McNabb, and A. F. Lant. Pharmacokinetic and pharmacodynamic actions of enalapril in humans: Effect of probenecid pretreatment. J. Pharmacol. Exp. Ther. 253:362–368 (1990). · DOI
  30. A. R. Kugler, S. C. Olsen, and D. E. Smith. Tubular transport mechanism of quinapril and quinaprilat in the isolated perfused rat kidney: Effect of organic anions and cations. J. Pharmacokin. Biopharm. 24:349–368 (1996). · DOI
  31. H. Saitoh, C. Gerard, and B. J. Aungst. The secretory intestinal transport of some betalactam antibiotics and anionic compounds: a mechanism contributing to poor oral absorption. J. Pharmacol. Exp. Ther. 278:205–211 (1996). · DOI
  32. S. Hsing, Z. Gatmaitan, and I. M. Arias. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 102:897–885 (1992). · DOI
  33. M. Inoue, R. Kinne, T. Tran, L. Biempica, and I. M. Arias. Rat liver canalicular membrane vesicles: isolation and topological characterization. J. Biol. Chem. 258:5183–5188 (1983). · DOI
  34. A. Szewczuk, H. Milnerowicz, M. V. Polosatov, and K. A. Sobiech. Immunofluorescent localization of gamma-glutamyltransferase in rat and bovine tissues. Acta Histochem. 66:152–159 (1980). · DOI
  35. P. Meier, E. Szutl, A Reuben, and J. Boyer. Structural and functional polarity of canalicular and basolateral plasma membrane vesicles isolated in high yield from rat liver. J. Cell Biol. 98:991–1000 (1984). · DOI
  36. K. J. Ho, S. C. Hsu, J. S. Chen, and L. H. Ho. Human biliary beta-glucuronidase: correlation of its activity with deconjugation of bilirubin in the bile. Eur. J. Clin. Invest. 16:361–367 (1986). · DOI
  37. K. J. Ho, L. H. Ho, and O. R. Kruger. Characterization and determination of the activity of biliary beta-glucuronidase in rats. J. Lab. Clin. Med. 93:916–925 (1979).
  38. A. J. Lança and Y. Israel. Histochemical demonstration of sinusoidal γ-glutamyltransferase activity by substrate protection fixation: Comparative studies in rat and guinea pig liver. Hepatology 14:857–863 (1991). · DOI
  39. P. Maki. Pathogenesis of calcium bilirubinate gallstone: Role of E. coli, β-glucuronidase and coagulation by inorganic ions, polyelectrolytes and agitation. Ann. Surg. 164:90–100 (1966). · DOI
  40. K. J. Ho, L. H. C. Ho, and O. R. Kruger. Characterization and determination of the activity of biliary β-glucuronidase in rats. J. Lab. Clin. Med. 93:916–925 (1979).
  41. N. Ballatori, R. Jacob, and J. L. Boyer. Intrabiliary glutathione hydrolysis: A source of glutamate in bile. J. Biol. Chem. 261:7860–7865 (1986). · DOI

Cited by

Metadata

Authors
Sirianni, G. L., & Pang, K. S.
Affiliations
University of Toronto (CA)
Venue
Journal of Pharmacokinetics and Biopharmaceutics
Published
1997-08
Volume
25
Issue
4
Pages
449-470
ISSN
0090-466X (ISSN-L)
OpenAlex
W1538056146
Cited by
89
References
0
Citations by year
2025: 2 · 2024: 6 · 2023: 6 · 2022: 7 · 2021: 5 · 2020: 7 · 2019: 5 · 2018: 7 · 2017: 5 · 2016: 3 · 2015: 1 · 2013: 1 · 2012: 4
FWCI
0.99
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Pharmacokinetics and Biopharmaceutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01gm038250-09)
  • National Institute of General Medical Sciences (GM-38250)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
metabolic clearance, liver, kidney, enalapril, physiologically based pharmacokinetic modeling, biliary excretion, cellular metabolism, renal brush border, glomerular filtration, matrix inversion, esterolysis, area under the curve
MeSH terms
Animals, Enalapril, Kidney, Liver, Metabolic Clearance Rate, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review